Onco Actu du 12 juin 2015

	1. Biologie
ADAMTS family of genes may be the next ‘thing’ in ovarian cancer treatment [MD Anderson Cancer Center] MD Anderson study reveals key mutations other than well-known BRCA1/BRCA2 genes.
	2.7 Etiologie - Obésité
Weight tied to breast cancer risk in older women [Reuters] Women with BMIs of 35 and up were about 56 percent more likely to be diagnosed with any type of invasive breast cancer during the study, compared to normal-weight women.
	3.1 Tabac
Facebook and Twitter could be used to help people quit smoking [NHS Choices] The results of this study are promising and address a major public health issue.
Research shows most children do not regularly use e-cigarettes [Cancer Research UK] The findings reflect earlier research which shows that regular use of e-cigarettes is extremely rare among young non-smokers.
FDA’s New Research Videos on E-Cigarettes, Nicotine and Cigarillos [FDA Voice] Often research is focused on innovation and discovery to expand the body of scientific knowledge. Regulatory science is different—and exciting in its own way. How often do scientists get to see their research findings used to improve people’s lives? Tobacco regulatory scientists are doing just that.
	3.5 Prévention - UV
Should Tanning Bed Warnings Take A Cue From Graphic Cigarette Labels? [NPR] Douglas says it's important to tailor the public health message to the audience. Young people, who often consider themselves invincible, aren't as likely to respond to messages linking a habit to some likely far-off health outcome like lung cancer or early death.
	4. Dépistage, diagnostic et pronostic
Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020 [ReportsnReports] In the coming years, the cancer diagnostics market is expected to experience the highest growth rate in the Asian region, with emphasis on India and China. These countries are expected to serve as revenue pockets for companies operating in the cancer diagnostics market.
	4.1 Dép., diag. & prono. - Prostate
As Part of Choosing Wisely® Campaign, American Urological Association Identifies Second List of Commonly Used Tests and Treatments to Question [AUA] - Don’t obtain computed tomography scan of the pelvis for asymptomatic men with low-risk clinically localized prostate cancer. - Offer PSA testing for detecting prostate cancer only after engaging in shared decision making.
	4.12 Biopsies liquides
Personal Genome Diagnostics Launches LungSelect for Non-Invasive Detection of Clinically Actionable Mutations in Lung Cancer [Personal Genome Diagnostics] The LungSelect test is analyzed in PGDx’s CLIA laboratory. Results will be available in approximately two weeks.
NeoGenomics Launches Twelve NeoLAB™ "Liquid Biopsy" Tests for Hematologic Diseases [NeoGenomics] Physicians can utilize the new liquid biopsy tests to: 1) Screen patients to determine if a bone marrow biopsy is necessary, especially when myelodysplastic syndrome or acute leukemia is suspected; 2) Monitor disease status, response to therapy and predict early relapse; and 3) Complete testing when a bone marrow sample is inadequate or is technically difficult to obtain.
Genomic Health to Present Proof-of-Concept Bladder Cancer Liquid Biopsy Data at AACR Precision Medicine Meeting [Genomic Health] Results Demonstrate Company's Progress in Development of Urine Test for Monitoring of Bladder Cancer.
	5. Traitements
MD Anderson study finds gene mutations sensitize tumors to specific cancer drugs [MD Anderson Cancer Center] The study, published in Cancer Discovery, discovered that certain mutations in ARID1a (AT-rich interactive domain-containing protein 1a), a gene recently implicated in cancer progression, sensitize some tumors to PARP inhibitor drugs, such as olaparib, veliparib and BMN673, which block DNA damage repair pathways.
	5.4 Traitements - Economie
Blockbuster-to-be cancer meds outclass other big launches--except Sovaldi and statins [FiercePharma] The population of cancer patients is much, much smaller, and therapy tends to be short-lived. Even at their much higher prices--$150,000 or so for Merck's Keytruda and Bristol-Myers Squibb's Opdivo, for instance--matching statins would be quite a feat.
	5.5.3 ASCO (prostate)
Adjuvant Chemotherapy Improves Prostate Cancer Survival [National Cancer Institute] Dr. Sandler agreed, saying patients with the most aggressive cancers would be the best candidates for adjuvant docetaxel. “In intermediate, lower-risk subsets [of patients], I would not recommend it.”
	6. Lutte contre les cancers
Storytelling Helps Overcome Cervical Cancer Screening Disparities [National Cancer Institute] The findings are consistent with other NCI-supported research showing that culturally tailored narrative approaches to education and outreach can be important tools in promoting and changing health-related attitudes and behaviors, including increasing vaccination rates, encouraging people to quit smoking, and improving diet and physical activity.
	6.1 Observation
Comorbid Conditions Associated With Worse Lung Cancer Survival [AACR] Islam and colleagues found that among patients with localized lung cancer, those with one comorbidity had a 30 percent higher risk of mortality compared with those who had no comorbidity. Among patients with metastatic lung cancer, comorbidity had less impact on survival.
	6.11 Patients
When Doctors Withdraw Cancer Treatment [NY Times] We reviewed each possibility with our patient, both so he could hear our concerns, and to reassure ourselves that he wasn’t taking too much chemotherapy – our greatest fear. But we still couldn’t tell, as the most insight into each scenario he could give us being “Maybe.” So reluctantly, and after explaining our worries with our patient, we stopped his treatment.
	6.6 Publications
“Significant concerns” and formal investigation unwind Nature Nanotech sequencing paper [Retraction Watch] The editorial lists 10 researchers who “voiced their scientific concerns” about the paper. Yet, nowhere—not in the retraction notice nor in the editorial—does the journal actually describe what those scientific concerns were.
	6.7 DMP, Big Data & applis
Cancer patients offered access to their treatment records by a new online information portal [Cancer Research UK] While patients were generally in favour of the portal, clinicians were more cautious.
	6.8 Communication
Proton beam therapy claims refuted by urologists on Twitter [HealthNewsReview] Something posted on the website of the University of Florida Proton Therapy Institute sparked a mini-furor this week with a couple of urologists who are active on social media.